Dermapharm Holding SE (CHIX:DMPD) Net Income (Continuing Operations): €143 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DMPD Dermapharm Holding SE CHIX:DMPD
80 GF Score
Price €46.18
GF Value €44.98
! 5 Warning Signs
View Full Analysis

What is Dermapharm Holding SE Net Income (Continuing Operations)?

Dermapharm Holding SE CHIX:DMPD 80 Net Income (Continuing Operations) is €143 Mil as of Mar. 2026. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €44.98. The stock has 5 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Dermapharm Holding SE's Net Income (Continuing Operations) for the three months ended in Mar. 2026 was €45 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 was €143 Mil.

Dermapharm Holding SE  (CHIX:DMPd) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Dermapharm Holding SE Net Income (Continuing Operations) Related Terms

Dermapharm Holding SE Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Dermapharm Holding SE's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dermapharm Holding SE Net Income (Continuing Operations) Chart

Dermapharm Holding SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 208.90 132.62 60.53 111.74 131.35

Dermapharm Holding SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.20 20.89 41.11 36.15 45.13
CHIX:DMPD
80GF Score
Dermapharm Holding SE CHIX:DMPD
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dermapharm Holding SE Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €143 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of €143 Mil mean?
Dermapharm Holding SE (CHIX:DMPD) has a Net Income (Continuing Operations) of €143 Mil as of Mar. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Dermapharm Holding SE and its competitors.
Is Dermapharm Holding SE's Net Income (Continuing Operations) too high?
Dermapharm Holding SE's current Net Income (Continuing Operations) is €143 Mil. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Net Income (Continuing Operations) compare to ZTS and UTHR?
Dermapharm Holding SE's Net Income (Continuing Operations) of €143 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Drug Manufacturers company?
A good Net Income (Continuing Operations) depends on the Drug Manufacturers industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Dermapharm Holding SE and its competitors. Dermapharm Holding SE's current Net Income (Continuing Operations) is €143 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current Net Income (Continuing Operations) of €143 Mil. The stock's GF Value™ is €44.98, compared to a current price of €46.18 — trading 2.7% above its estimated fair value. The current Net Income (Continuing Operations) is €143 Mil. Dermapharm Holding SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current Net Income (Continuing Operations) is €143 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?

Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued. The current stock price of €46.18 is trading 2.7% above its estimated GF Value™ of €44.98.

Key valuation signals for CHIX:DMPD:

  • Net Income (Continuing Operations): €143 Mil
  • GF Value™: €44.98 vs. price of €46.18 (2.7% above fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dermapharm Holding SE Business Description

Other Exchanges DMPHF:USA0A5J:UKDMP:Germany
Address Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score

Get the complete analysis for CHIX:DMPD

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.18
Price
€44.98
GF Value